Cart
sales@molnova.com
BGB-283
CAS No. 1446090-77-2
BGB-283( Lifirafenib | BGB 283 | BGB283 )
Catalog No. M11891 CAS No. 1446090-77-2
BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBGB-283
-
NoteResearch use only, not for human use.
-
Brief DescriptionBGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM).
-
DescriptionBGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM); inhibits recombinant BRAFV600E with IC50 of 23 nM; also inhibits EGFR and EGFR T790M/L858R with IC50 of 29 nM and 495 nM respectively; potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation in vitro; shows tumor growth inhibition in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation.Colon Cancer Preclinical.
-
In Vitro——
-
In Vivo——
-
SynonymsLifirafenib | BGB 283 | BGB283
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1446090-77-2
-
Formula Weight478.4227
-
Molecular FormulaC25H17F3N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 125 mg/mL
-
SMILES[H][C@@]1(C2=CC(OC3=C(CCC4=O)C(N4)=NC=C3)=CC=C2O[C@]51[H])[C@@H]5C6=NC7=CC=C(C=C7N6)C(F)(F)F
-
Chemical Name1,8-Naphthyridin-2(1H)-one, 5-[[(1R,1aS,6bR)-1a,6b-dihydro-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-cyclopropa[b]benzofuran-5-yl]oxy]-3,4-dihydro-, rel-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tang Z, et al. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
2. Cancer Discov. 2016 Jul;6(7):OF1.
molnova catalog
related products
-
I-37
I-37 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
-
Effusanin A
Effusanin A has antibacterial activity. It exhibits DNA-damaging activity in assay which employed DNA-repair deficient (RAD 52Y) and repairs proficient (RAD +) yeast strains. Effusanin A shows inhibitory effects on DU145 cells with IC50 value of 3.16 μM, and LoVo cells with IC50 value of 3.02 μM.
-
GDC-0349
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.
